Drug Trial Radar · NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
790
Actual
Start
Sep 26, 2006
Primary completion
Dec 23, 2013
Study completion Jan 31, 2025
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 3, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer. PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Conditions
- Metastatic Hormone-sensitive Prostate Cancer
Interventions
androgen-deprivation therapyDrug
LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
docetaxelDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry
Locations
343 sites in 1 country. Site status is shown where the registry gives one.
Providence Cancer Center
Anchorage, Alaska
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic Scottsdale
Scottsdale, Arizona
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California
Peninsula Medical Center
Burlingame, California
California Cancer Care, Incorporated - Greenbrae
Greenbrae, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California
Mather Veteran Affairs Medical Center
Mather, California
Mercy Cancer Center at Mercy Medical Center
Merced, California
Memorial Medical Center
Modesto, California
Sutter Health - Western Division Cancer Research Group
Novato, California
University of California Davis Cancer Center
Sacramento, California
California Pacific Medical Center - California Campus
San Francisco, California
Sutter Pacific Medical Foundation
Santa Rosa, California
Saint Helena Hospital
St. Helena, California
Tahoe Forest Cancer Center
Truckee, California
Sutter Solano Medical Center
Vallejo, California
University of Colorado Cancer Center at UC Health Sciences Center
Aurora, Colorado
Veterans Affairs Medical Center - Denver
Denver, Colorado
Shaw Regional Cancer Center
Edwards, Colorado
Poudre Valley Hospital
Fort Collins, Colorado
Front Range Cancer Specialists
Fort Collins, Colorado
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado
Montrose Memorial Hospital Cancer Center
Montrose, Colorado
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut
Yale Cancer Center
New Haven, Connecticut
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia
George Washington University Medical Center
Washington D.C., District of Columbia
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida
University of Florida Shands Cancer Center
Gainesville, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida
CCOP - Mount Sinai Medical Center
Miami Beach, Florida
Northeast Georgia Medical Center
Gainesville, Georgia
Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho
Showing 40 of 343 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.